Dr. Schmidt is a Senior Director in Experimental Medicine for Janssen Pharmaceutica, N.V. in Beerse, Belgium. He received his medical degree from the University of Chicago in 1983 and entered postgraduate training in psychiatry and clinical service in the US Navy. Following Naval service, Dr. Schmidt was a research fellow in the National Institute of Mental Health (NIMH) intramural program where he focused on the use of functional imaging as a pharmacodynamic marker. Following fellowship, he worked at Lilly Research Laboratories, Novartis, and now Janssen. He has been responsible for clinical testing of NMEs for psychiatric indications through proof of concept, provided guidance to micro PET and MRI studies of Alzheimer’s transgenic mouse studies, and has led a preclinical imaging group for development of site specific PET tracers and then qualifying them in human. He supervised multisite [11C] PiB amyloid PET substudies for the Phase 3 trials of bapineuzumab and co-leads the advanced disease modeling work package in AMYPAD. He has authored or coauthored over 75 peer-reviewed manuscripts, reviews, and book chapters on the use of in vivo imaging for CNS drug development.